During the European Hematology Association (EHA) 2023 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint session entitled 'The ins and outs of CAR T-cells in the real world'.

Here, we share the presentation of Professor Kieron Dunleavy, George Washington University Cancer Center, Washington, US, on the topic of biomarkers and eligibility for CAR T-cell therapies in diffuse large B-cell lymphoma (DLBCL).

Dunleavy begins by providing an overview of approved CAR T-cell products, comparing the trials that led to their approval and discussing their use in second-line aggressive large B-cell Lymphoma (LBCL). Dunleavy then explains the factors that determine CAR T-cell response, outlining the molecular biology and classification of DLBCL. Evidencing the ZUMA-7 and TRANSFORM trials, Dunleavy identifies important biomarkers in DLBCL before referencing both clinical trial and real-world data to discuss the efficacy of CAR T-cell therapies.

This activity was supported through an educational grant from Bristol Myers Squibb.

свернуть